Arterial stiffness and carotid intima-media thickness in HIV infected: Patients

Medical Ultrasonography

Volumn 13, Issue 2, 2011, Pages 127-134

  Papiţǎ, Anamaria ^a   Albu, Adriana ^a   Fodor, Daniela ^a   Itu, Corina ^a   Cârstina, Dumitru ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

Arterial stiffness; Carotid intima media thickness; HIV infection

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY COMPLIANCE; ARTERY INTIMA; ARTERY MEDIA; ARTICLE; BRACHIAL ARTERY; CARDIOVASCULAR RISK; CAROTID ARTERY; CASE CONTROL STUDY; COMMON CAROTID ARTERY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; ECHOGRAPHY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PULSE WAVE;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; STATISTICS, NONPARAMETRIC; TUNICA INTIMA; TUNICA MEDIA;

EID: 80052764933     PISSN: 18444172     EISSN: 20668643     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Savès M, Chêne G, Ducimetière P, et al. French WHO MONICA Project and the APROCO (ANRS EP11) Study Group. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37: 292-298.
2. Lewden C, May T, Rosenthal E, et al. Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The "Mortalite 2000 and 2005" Surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48: 590-598.
3. Sterne JS, Hernan MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 2005; 366: 378-384.
4. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351: 1328.
5. Das S, Shahmanesh M, Stolinski M, et al. In treatmentnaive and antiretroviral-treated subjects with HIV, reduced plasma adiponectin is associated with a reduced fractional clearance rate of VLDL, IDL and LDL apolipoprotein B-100. Diabetologia 2006; 49: 538-542.
6. Mallon PW, Miller J, Kovacic JC, et al. Effect of pravas tatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study. AIDS 2006; 20: 1003-1010.
7. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 2479-2486.
8. Coplan PM, Nikas A, Japour A, et al. Incidence of myocardial infarction in randomized clinical trials of protease inhibitor-based antiretroviral therapy: an analysis of four different protease inhibitors. AIDS Res Hum Retroviruses 2003;19:449-455.
9. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with HIV disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
10. DAD Study Group, Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
11. Tabib A, Greenland T, Mercier I, et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet 1992; 340: 730.
12. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
13. Echevarria KL, Hardin TC, Smith JA. Hyperlipidemia associated with protease inhibitor therapy. Ann Pharmacother 1999; 33: 859-863.
14. Mirete G, Masia M, Gutierrez F, Mora A, Escolano C, Maestre A. Acute pancreatitis as a complication of ritonavir therapy in a patient with AIDS. Eur J Clin Microbiol Infect Dis 1998; 17: 810-811.
15. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76: 559-565.
16. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997; 96: 1432-1437.
17. Lorenz MW, von Kegler S, Steinmetz H, Markus HS, Sitzer M. Carotid intima-media thickening indicates a higher vascular risk across a wide age range: prospective data from the Carotid Atherosclerosis Progression Study (CAPS). Stroke 2006; 37: 87-92.
18. Willum-Hansen T, Staessen J.A, Torp-Pedersen C, et al. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006; 113: 664-670.
19. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
20. Laurent S, Cockroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 27: 2588-2605.
21. Harada A, Okada T, Niki K, Chang D, Sugawara M. Online noninvasive one-point measurements of pulse wave velocity. Heart Vessels 2002; 17: 61-68.
22. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. Arthritis Rheum 2002; 46: 1489-1497.
23. Schillaci G, De Socio GV, Pucci G, et al. Aortic stiffness in untreated adult patients with human immunodeficiency virus infection. Hypertension 2008; 52: 308-313.
24. Hsue PY, Lo JC, Franklin A, et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 1603-1608.
25. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS 2006; 20: 2275-2283.
26. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000; 14: F123-F128.
27. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001; 15: 329-334.
28. Lorenz MW, Stephan C, Harmjanz A, et al. Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis. Atherosclerosis 2008; 196: 720-726.
29. Currier JS, Kendall MA, Zackin R, et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005: 19: 927-933.
30. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIVpositive patients treated with protease inhibitors. Atherosclerosis 2002; 162: 433-438.
31. de Saint Martin L, Vandhuick O, Guillo P, et al. Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006; 185: 361-367.
32. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 2005; 25: 932-943.
33. McEniery CM, Wilkinson IB. Large artery stiffness and inflammation. J Hum Hypertens 2005; 19: 507-509.
34. Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999.
35. van Vonderen MG, Smulders YM, Stehouwer CD, et al. Carotid-intima media thickness and arterial stiffness in HIVinfected patients: the role of HIV, antiretroviral therapy, and lipodystrophy. J Acquir Immune Defic Syndr 2009; 50: 153-161.
36. Henry RM, Kostense PJ, Spijkerman AM, et al. Arterial stiffness increases with deteriorating glucose tolerance status: the Hoorn Study. Circulation 2003; 107: 2089-2095.
37. Phillips AN, Carr A, Neuhaus J, et al. Interruption of ART and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART Trial. Antivir Ther 2008; 13: 177-187.
38. Calmy A, Nguyen A, Montecucco F, et al. HIV activates markers of cardiovascular risk in a randomized treatment interruption trial: STACCATO. Presented at: 15th Conference on Retroviruses and Opportunistic Infections (CROI), 2008, Boston, MA. Abstr.
39. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-1338.
40. Carr A, Miller J, Law M, Coopr DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000; 14: F25-F32.
41. Hellerstein MK, Grunfeld C, Wu K, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993; 76: 559-565.
42. Dijk JM, Algra A, van der Graff Y, Grobbee DE, Bots ML. SMART study group. Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The SMART study. Eur Heart J 2005; 26: 1213-1220.